-
Mashup Score: 0CAR T-cell benefit in lenalidomide-refractory myeloma - 10 month(s) ago
“Early CAR Ts demonstrating efficacy and safety and prior lines of treatment impact survival from CAR T in myeloma. Can this also be true for multiple myeloma?”
Source: www.mdedge.comCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 1
No increased risk to patients with other hematologic malignancies, meta-analysis shows
Source: www.medpagetoday.comCategories: Latest Headlines, Oncologists2Tweet
-
Mashup Score: 2Using REVLIMID as a Successful Treatment for Myeloma Patients with Kidney Involvement - 2 year(s) ago
Recorded on September 14th, 2022 as part of the Myeloma Kidney Involvement Chapter in the Myeloma Crowd Community by HealthTree Program with Marc Braunstein,…
Source: YouTubeCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 1
ClinicalTrials.gov Identifier: NCT02969837.
Source: PubMedCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 1Loss Of COP9-Signalosome Genes At 2q37 Is Associated With IMiD Agent Resistance In Multiple Myeloma - PubMed - 2 year(s) ago
The acquisition of a multi-drug refractory state is a major cause of mortality in myeloma. Myeloma drugs that target the Cereblon (CRBN) protein include widely-used immunomodulatory drugs (IMiDs), and newer CRBN E3 ligase modulator drugs (CELMoDs), in clinical trials. CRBN genetic disruption causes …
Source: PubMedCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0The Stem Cell Transplant Daily - 2 year(s) ago
A selection of articles, blog posts, videos and photos recommended by Muzaffar Qazilbash
Source: paper.liCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 1
Our analysis showed that an adequate dose of carfilzomib is important for achieving the best survival benefits in a real-world setting. Adverse effects after KRd and Kd therapy should also be considered.
Source: PubMedCategories: Hem/Oncs, Latest HeadlinesTweet-
#Myeloma Paper of the Day: Study from Japan of real-world effectiveness of #Kyprolis/#Revlimid/dex (KRd) & Kd finds median PFS & OS were 8.8 & 29.3 mos. for KRd; 7.1 and 20.9 mos. for Kd in cohort where >50% were #Velcade- or #Revlimid-refractory: https://t.co/iEfPJzWNGg. #mmsm https://t.co/let7HqCcOu
-
-
Mashup Score: 0Combination elotuzumab and lenalidomide treatment efficacy is dependent on crosstalk between NK cells, monocytes and myeloma cells - PubMed - 2 year(s) ago
Patients with refractory relapsed multiple myeloma (RRMM) respond to Elotuzumab (Elo) and lenalidomide (Len) combination treatment. The mechanisms underlying this observation are not fully understood. Furthermore, predictive biomarkers of response have not been revealed to date. To address these iss …
Source: PubMedCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0The Stem Cell Transplant Daily - 2 year(s) ago
A selection of articles, blog posts, videos and photos recommended by Muzaffar Qazilbash
Source: paper.liCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 1
In patients with multiple myeloma, MRD status at both ASCT + 3 and ASCT + 9 is a powerful predictor of PFS and OS.
Source: PubMedCategories: Hem/Oncs, Latest HeadlinesTweet
#CART-cell benefit in #Lenalidomide-refractory #Myeloma 👉https://t.co/ofFJhlzktZ @MDedgeHemOnc #Revlimid https://t.co/5gah3OHF6Q